Effect of Hydroxychloroquine on Proteinuria and Inflammatory Markers in Chronic Glomerulopathy (CGN): A Randomized Controlled Trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20250319019

Enrollment

Registered

2025-03-19

Start date

2024-04-02

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic glomerulopathy patients with a urine protein to creatinine ratio (UPCR) more than or equal to 0.5 g/g and an estimated glomerular filtration rate (eGFR) of more than 20 mL/min/1.73 m2 Chronic glomerulopathy, hydroxychloroquine, proteinuria, interleukin-6

Interventions

Dose of hydroxychloroquine 200 mg orally (1 tablet) twice daily for patients with eGFR of more than 60 mL/min/1.73 m2, 300 mg orally (1.5 tablets) once daily for patients with eGFR between 45 and 59 m

Experimental Drug,Placebo Comparator Drug

Hydroxychloroquine (HCQ),Placebo

Eligibility

Sex/Gender

All

Age

20 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age over 20 years, 2. A diagnosis of CGN from any causes with or without biopsy-proven CGN, 3. Estimated glomerular filtration rate (eGFR) of more than 20 mL/min/1.73 m2 (calculated using the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] creatinine equation), 4. Protein excretion of at least 0.50 grams per day despite receiving a maximum tolerable dose of renin-angiotensin-aldosterone system (RAAS) inhibitor for at least 3 months, 5. Inform consent

Exclusion criteria

Exclusion criteria: 1. Use of systemic immunosuppressive therapy except for maintenance low dose steroid at the time of enrollment, 2. An indication for a new regimen of corticosteroids (crescentic IgAN or minimal change disease with IgA deposits), 3. Contraindications for HCQ therapy, 4. Severe and uncontrolled comorbid diseases, 5. Current or planned pregnancy or lactation

Design outcomes

Primary

Measure	Time frame
Protein excretion At baseline, 2 months, and months after intervention Urine protein to creatinine ratio	—

Secondary

Measure	Time frame
Interleukin-6 At baseline, 2 months, and months after intervention Serum interleukin-6,High sensitivity C-reactive protein (hsCRP) At baseline, 2 months, and months after intervention Serum hsCRP,Glomerular filtration rate (GFR) At baseline, 2 months, and months after intervention Glomerular filtration rate (GFR)	—

Countries

Thailand

Contacts

Public ContactThitirat Supasil

Phramongkutklao hospital

thitirat_meaw@hotmail.com0817071114

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026